Abstract

Prostate cancer remains a common cancer diagnosis and cause of cancer-related death in men. Despite its high prevalence, screening for prostate cancer for early detection remains controversial. This article outlines evidence from contemporary prostate cancer screening clinical trials and presents an overview of therapeutic options across the spectrum of prostate-cancer states.